-
A recurrent NTRK1 tyrosine kinase domain mutation pair is characteristic in a subset of dedifferentiated liposarcomas Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-14 Zoltán Lippai, Bálint Péterfia, Gergő Papp, Katalin Dezső, Gábor Bedics, Zsuzsanna Pápai, Meindert H Lamers, Rosan CM Kuin, Károly Szuhai, Zoltán Sápi
Dedifferentiated liposarcoma (DDLPS) is a common form of liposarcoma with challenging treatment modalities. Pan-TRK immunopositivity can be often observed without gene fusion in soft tissue sarcomas with myogenic differentiation. Expression and the role of in DDLPS are under-studied. We sought to identify activating mutations of the genes. 131 DDLPS patients were selected for pan-TRK immunohistochemistry
-
Biliary Tract Cancers: French National Clinical Practice Guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, AFEF, SFRO, SFP, SFR, ACABi, ACHBPT) Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-13 Gael S Roth, Loic Verlingue, Matthieu Sarabi, Jean-Frédéric Blanc, Emmanuel Boleslawski, Karim Boudjema, Anne-Laure Bretagne-Bignon, Marine Camus-Duboc, Romain Coriat, Gilles Créhange, Thierry De Baere, Christelle de la Fouchardière, Clarisse Dromain, Julien Edeline, Maximiliano Gelli, Boris Guiu, Samy Horn, Valérie Laurent-Croise, Côme Lepage, Astrid Lièvre, Anthony Lopez, Sylvain Manfredi, Julie
This document is a summary of the French intergroup guidelines of the management of biliary tract cancers (BTC) (intrahepatic, perihilar and distal cholangiocarcinomas, and gallbladder carcinomas) published in September 2023, available on the website of the French Society of Gastroenterology (SNFGE) (www.tncd.org). This collaborative work was conducted under the auspices of French medical and surgical
-
Fertility and reproductive concerns related to the new generation of cancer drugs and the clinical implication for young individuals undergoing treatments for solid tumors Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-11 Hildur Helgadottir, Alexios Matikas, Josefin Fernebro, Jan-Erik Frödin, Simon Ekman, Kenny A. Rodriguez-Wallberg
The treatment landscape of solid tumors has changed markedly in the last years. Molecularly targeted treatments and immunotherapies have been implemented and have, in many cancers, lowered the risk of relapse and prolonged survival. Patients with tumors harboring specific targetable molecular alterations or mutations are often of a younger age, and hence future fertility and family building can be
-
A three-arm randomised Phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel in metastatic uveal melanoma Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-11 Joseph J Sacco, Richard Jackson, Pippa Corrie, Sarah Danson, T.R. Jeffry Evans, Sebastian Ochsenreither, Satish Kumar, Andrew Goodman, James Larkin, Ioannis Karydis, Neil Steven, Paul Lorigan, Ruth Plummer, Poulam Patel, Eftychia Psarelli, Anna Olsson-Brown, Heather Shaw, Serge Leyvraz, Louise Handley, Charlotte Rawcliffe, Paul Nathan
The MAPK pathway is constitutively activated in uveal melanoma (UM). Selumetinib (AZD6244, ARRY-142886), a MEK inhibitor, has shown limited activity as monotherapy in metastatic UM. Pre-clinical studies support synergistic cytotoxic activity for MEK inhibitors combined with taxanes, and here we sought to assess the clinical efficacy of combining selumetinib and paclitaxel. Seventy-seven patients with
-
A Global Phase II Randomized trial comparing Oral Taxane ModraDoc006/r to Intravenous Docetaxel in Metastatic Castration Resistant Prostate Cancer Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-11 Ulka N. Vaishampayan, Marianne Keessen, Robert Dreicer, Elisabeth I. Heath, Tomas Buchler, Péter F. Árkosy, CsosziTibor Csöszi, Pawel Wiechno, Evgeny Kopyltsov, Sergey V. Orlov, Alexey Plekhanov, Maria Smagina, Sergei Varlamov, Neal D. Shore
ModraDoc006, an oral formulation of docetaxel, is co-administered with the cytochrome P450-3A4 and P-glycoprotein inhibitor, ritonavir (r): ModraDoc006/r. The preliminary efficacy and safety of oral ModraDoc006/r was evaluated in a global randomized phase II trial and compared to the current standard chemotherapy regimen of intravenous (i.v.) docetaxel and prednisone. 103 mCRPC patients, chemotherapy-naïve
-
Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-11 Alessandro Leonetti, Fabiana Perrone, Matteo Puntoni, Giuseppe Maglietta, Paola Bordi, Emilio Bria, Emanuele Vita, Francesco Gelsomino, Andrea De Giglio, Alain Gelibter, Marco Siringo, Francesca Mazzoni, Enrico Caliman, Carlo Genova, Federica Bertolini, Giorgia Guaitoli, Francesco Passiglia, Marco Donatello Delcuratolo, Michele Montrone, Giulio Cerea, Giulia Pasello, Elisa Roca, Lorenzo Belluomini
The aim of this multi-center, retrospective/prospective cohort observational study was to evaluate outcomes in routine clinical practice of first-line chemo-immunotherapy with cis/carboplatin, pemetrexed and pembrolizumab in patients with advanced non-squamous non-small cell lung cancer (NSCLC) in 33 Italian centers. The outcome measure was to evaluate overall survival (OS) in a real-world patient
-
Prognosis of glioblastoma patients improves significantly over time interrogating historical controls Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-11 Thomas A, Tran S, El Houari L, Seyve A, Bielle F, Birzu C, Lozano-Sanchez F, Mokhtari K, Giry M, Marie Y, Laigle-Donadey F, Dehais C, Houillier C, Psimaras D, Alentorn A, Laurenge A, Touat M, Sanson M, Hoang-Xuan K, Kas A, Rozenblum L, Habert M-O, Nichelli L, Leclercq D, Galanaud D, Jacob J, Karachi C, Capelle L, Carpentier A, Mathon B, Belin L, Idbaih A
Glioblastoma (GBM) is the most common devastating primary brain cancer in adults. In our clinical practice, median overall survival (mOS) of GBM patients seems increasing over time. To address this observation, we have retrospectively analyzed the prognosis of 722 newly diagnosed GBM patients, aged below 70, in good clinical conditions ( Karnofsky Performance Status –KPS- above 70%) and treated in
-
Assessing the clinical benefit of systemic anti-cancer treatments in the Netherlands: The impact of different thresholds for effectiveness Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-11 Brenda Leeneman, Nicolas S.H. Xander, W. Edward Fiets, Wouter K. de Jong, Nathalie E.M. Uyl, A.N. Machteld Wymenga, An K.L. Reyners, Carin A. Uyl-de Groot
In the Netherlands, the clinical benefit of systemic anti-cancer treatments (SACTs) is assessed by the Committee for the Evaluation of Oncological Agents (cieBOM). For non-curative SACTs, the assessment is based on the hazard ratio (HR) for progression-free survival and/or overall survival (OS), and the difference in median survival. We evaluated the impact of different thresholds for effectiveness
-
Chemo-immunotherapy with dinutuximab beta in patients with relapsed/progressive high-risk neuroblastoma: does chemotherapy backbone matter? Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-11 Patricia Raiser, Gudrun Schleiermacher, Marion Gambart, Benoit Dumont, Anne-Sophie Defachelles, Estelle Thebaud, Julie Tandonnet, Claudia Pasqualini, Stéphanie Proust, Natacha Entz-Werle, Isabelle Aerts, Lee A. Ndounga-Diakou, Arnaud Petit, Chloe Puiseux, Camille Khanfar, Jeremie Rouger, Ludovic Mansuy, Joy Benadiba, Frédéric Millot, Claire Pluchart, Salim Laghouati, Birgit Geoerger, Gilles Vassal
Addition of anti-GD2 antibodies to temozolomide-based chemotherapy has demonstrated increased antitumor activity and progression-free survival in patients with relapsed/progressive high-risk neuroblastoma. However, chemo-immunotherapy is not yet approved for this indication. This study presents the chemo-immunotherapy experience in patients with relapsed/progressive high-risk neuroblastoma treated
-
A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-11 Xiaoting Wei, Zhengyun Zou, Weizhen Zhang, Meiyu Fang, Xiaoshi Zhang, Zhiguo Luo, Jing Chen, Gang Huang, Peng Zhang, Ying Cheng, Jiwei Liu, Jiyan Liu, Junping Zhang, Di Wu, Yu Chen, Xiaobiao Ma, Hongming Pan, Renbing Jiang, Xinlan Liu, Xiubao Ren, Hongqi Tian, Zhongwei Jia, Jun Guo, Lu Si
-mutant melanoma is an aggressive subtype with poor prognosis; however, there is no approved targeted therapy to date worldwide. We conducted a multicenter, single-arm, phase II, pivotal registrational study that evaluated the efficacy and safety of the MEK inhibitor tunlametinib in patients with unresectable, stage III/IV, NRAS-mutant melanoma (NCT05217303). The primary endpoint was objective response
-
How to develop new systemic treatments in ultra-rare cancers with high unmet needs? The case of alveolar soft-part sarcoma Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-11 Silvia Stacchiotti, Gauthier Bouche, Ralf Herold, Pan Pantziarka, Kathrin Schuster, Roger Wilson, Francesco Pignatti, Bernd Kasper
Developing new drugs or generating evidence for existing drugs in new indications for ultra-rare cancers is complex and carries a high-risk of failure. This gets even harder in ultra-rare tumours, which have an annual incidence of 1 per 1,000,000 population or less. Here, we illustrate the problem of adequate evidence generation in ultra-rare tumours, using Alveolar Soft-Part Sarcomas (ASPS) – an ultra-rare
-
Corrigendum to “Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial” [Eur J Cancer 199 (2024) 113531] Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-09 Anna Maria Di Giacomo, Vanna Chiarion-Sileni, Michele Del Vecchio, Pier Francesco Ferrucci, Michele Guida, Pietro Quaglino, Massimo Guidoboni, Paolo Marchetti, Elena Simonetti, Federica Santangelo, Giovanni Amato, Alessia Covre, Roberto Camerini, Monica Valente, Mario Mandalà, Diana Giannarelli, Luana Calabrò, Michele Maio
-
Sentinel lymph node risk prognostication in primary cutaneous melanoma through tissue-based profiling, potentially redefining the need for sentinel lymph node biopsy Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-08 Julian Kött, Noah Zimmermann, Tim Zell, Alessandra Rünger, Isabel Heidrich, Glenn Geidel, Daniel J. Smit, Inga Hansen, Finn Abeck, Dirk Schadendorf, Alexander Eggermont, Suzana Puig, Axel Hauschild, Christoffer Gebhardt
The role of Sentinel Lymph Node Biopsy (SLNB) is pivotal in the contemporary staging of cutaneous melanoma. In this review, we examine advanced molecular testing platforms like gene expression profiling (GEP) and immunohistochemistry (IHC) as tools for predicting the prognosis of sentinel lymph nodes. We compare these innovative approaches with traditional staging assessments. Additionally, we delve
-
Trastuzumab plus pertuzumab for HER2-amplified advanced colorectal cancer: Results from the drug rediscovery protocol (DRUP) Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-07 Ilse A.C. Spiekman, Laurien J. Zeverijn, Birgit S. Geurts, Karlijn Verkerk, Soemeya F. Haj Mohammad, Vincent van der Noort, Paul Roepman, Wendy W.J. de Leng, Anne M.L. Jansen, Elske C. Gootjes, Derk-Jan A. de Groot, Emile D. Kerver, Theo van Voorthuizen, Jeanine M.L. Roodhart, Liselot B.J. Valkenburg-van Iersel, Hans Gelderblom, Emile E. Voest, Henk M.W. Verheul
In 2–5% of patients with colorectal cancer (CRC), human epidermal growth factor 2 ( is amplified or overexpressed. Despite prior evidence that anti-HER2 therapy confers clinical benefit (CB) in one-third of these patients, it is not approved for this indication in Europe. In the Drug Rediscovery Protocol (DRUP), patients are treated with off-label drugs based on their molecular profile. Here, we present
-
-
FGF amplification an important targeted for head and neck cancer patient? A case report of a patient with FGF amplification treated with erdafitinib Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-02 Nyere Gibson, Mathieu Larroquette, Charlotte Domblides, Felix Lefort, Amaury Daste
-
Corrigendum to “Risk factors for early-onset pancreatic ductal adenocarcinoma: A systematic literature review” [Eur J Cancer 198 (2024) 113471] Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-02 Sreenivasa R. Chandana, Laura M. Woods, Fiona Maxwell, Ruth Gandolfo, Tanios Bekaii-Saab
-
Clinical evaluation of a low-coverage whole-genome test for detecting homologous recombination deficiency in ovarian cancer Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-02 Romain Boidot, Michael G.B. Blum, Marie-Pierre Wissler, Céline Gottin, Jiri Ruzicka, Sandy Chevrier, Tiffany M. Delhomme, Jérome Audoux, Adrien Jeanniard, Pierre-Alexandre Just, Philipp Harter, Sandro Pignata, Antonio González-Martin, Christian Marth, Johanna Mäenpää, Nicoletta Colombo, Ignace Vergote, Keiichi Fujiwara, Nicolas Duforet-Frebourg, Denis Bertrand, Nicolas Philippe, Isabelle Ray-Coquard
The PAOLA-1/ENGOT-ov25 trial showed that maintenance olaparib plus bevacizumab increases survival of advanced ovarian cancer patients with homologous recombination deficiency (HRD). However, decentralized solutions to test for HRD in clinical routine are scarce. The goal of this study was to retrospectively validate on tumor samples from the PAOLA-1 trial, the decentralized SeqOne assay, which relies
-
The RANKL inhibitor denosumab in combination with dual checkpoint inhibition is associated with increased CXCL-13 serum concentrations Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-02 Katrin Schaper-Gerhardt, Ralf Gutzmer, Yenny Angela, Lisa Zimmer, Elisabeth Livingstone, Dirk Schadendorf, Jessica C. Hassel, Carsten Weishaupt, Bernhard Remes, Linda Kubat, Ivelina Spassova, Jürgen C. Becker
Recent evidence suggests additional immunomodulatory properties of RANKL inhibition possibly boosting the clinical efficacy of immune checkpoint inhibitors (ICI). We conducted a prospective, multicentre clinical trial in unresectable stage IV melanoma patients with bone metastases who received denosumab in parallel with dual ICI (BONEMET) and performed comprehensive immune monitoring at baseline and
-
Propranolol monotherapy in angiosarcoma – A window-of-opportunity study (PropAngio) Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-02 Alaa Embaby, Kimberley M. Heinhuis, Nikki S. IJzerman, Anne Miek Koenen, Stephanie van der Kleij, Ingrid Hofland, Hester van Boven, Joyce Sanders, Winette T.A. van der Graaf, Rick L. Haas, Alwin D.R. Huitema, Winan J. van Houdt, Neeltje Steeghs
Angiosarcoma is a rare and aggressive cancer of the endothelial cells. Propranolol, a non-selective β-blocker, was able to initiate apoptosis in angiosarcoma cell lines and its anti-tumor activity has been described in several case reports. The aim of this trial was to prospectively evaluate the anti-tumor activity of propranolol monotherapy in patients with angiosarcoma before proceeding to standard
-
Clinical and prognostic differences in oropharyngeal squamous cell carcinoma in USA and Denmark, two HPV high-prevalence areas Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-02 Amanda-Louise Fenger Carlander, Simone Kloch Bendtsen, Jacob H. Rasmussen, Kathrine Kronberg Jakobsen, Martin Garset-Zamani, Christian Grønhøj, Jeppe Friborg, Katherine Hutcheson, Faye M. Johnson, Clifton D. Fuller, Amy C. Moreno, Toyin Babarinde, Neil D. Gross, Jeffrey N. Myers, Christian von Buchwald
Uncertainty persists regarding clinical and treatment variations crucial to consider when comparing high human papillomavirus (HPV)-prevalence oropharyngeal squamous cell carcinoma (OPSCC) cohorts for accurate patient stratification and replicability of clinical trials across different geographical areas. OPSCC patients were included from The University of Texas MD Anderson Cancer Center (UTMDACC)
-
Clinicopathologic features, concurrent genomic alterations, and clinical outcomes of patients with KRAS G12D mutations in resected lung adenocarcinoma Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-02 Hang Cao, Zelin Ma, Qingyuan Huang, Han Han, Yuan Li, Yang Zhang, Haiquan Chen
In light of the ongoing clinical development of KRAS G12D-specific inhibitors, we sought to investigate the clinicopathologic, co-occurring genomic features and outcomes of patients with KRAS G12D-mutant lung adenocarcinoma. 3828 patients with completely resected primary lung adenocarcinomas were examined for KRAS mutations between 2008 and 2020. The association between KRAS G12D and clinicopathologic
-
UV1 telomerase vaccine with ipilimumab and nivolumab as second line treatment for pleural mesothelioma – A phase II randomised trial Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-01 Vilde Drageset Haakensen, Åsa Kristina Öjlert, Solfrid Thunold, Saima Farooqi, Anna K. Nowak, Wee L. Chin, Oscar Grundberg, Weronika Maria Szejniuk, Susana Cedres, Jens Benn Sørensen, Tonje Sofie Dalen, Marius Lund-Iversen, Maria Bjaanæs, Åslaug Helland
The NIPU-trial investigates the effect of adding the telomerase vaccine UV1 to treatment with ipilimumab and nivolumab for patients with pleural mesothelioma (PM). In this phase 2 open-label trial, patients with PM progressing after first-line chemotherapy were randomised to receive ipilimumab and nivolumab alone (arm B) or combined with UV1 (arm A). The primary endpoint was progression-free survival
-
A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidedness Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-01 Takayuki Yoshino, Naushin Hooda, Diana Younan, Kei Muro, Kohei Shitara, Volker Heinemann, Bert Howard O’neil, Fernando Rivera Herrero, Marc Peeters, Junpei Soeda, Mina Suh, Heidi Reichert, Khalid Mezzi, Jon Fryzek, Victoria Chia, Marko Rehn, Sebastian Stintzing
The first-line treatment choice of EGFRIs plus doublet chemotherapy vs. bevacizumab plus doublet chemotherapy remains a topic of interest for patients with left-sided RAS WT mCRC. We conducted a systematic literature review and meta-analysis of clinical trial data published between 2015 and 2024. We evaluated the relative efficacy and safety of first-line EGFRIs plus doublet chemotherapy (FOLFIRI or
-
Disease-free survival as a surrogate for overall survival in HR+/HER2– early breast cancer: A correlation analysis Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-01 Michael Untch, David Pérol, Erica L. Mayer, Javier Cortes, Arnd Nusch, David Cameron, Carlos Barrios, Thomas Delea, Andrii Danyliv, Namita Mishra, Rhea Gupta, Purnima Pathak, Peter A. Fasching
Overall survival (OS) is a universally accepted measure of clinical benefit; however, prolonged follow-up is needed to observe sufficient events. Disease-free survival (DFS) has been widely adopted as a primary endpoint for early breast cancer (EBC) trials, as follow-up is comparatively shorter. Here, we present an analysis evaluating DFS as a surrogate for OS for adjuvant treatment of hormone rec
-
Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-01 Lea Jessica Albrecht, Florentia Dimitriou, Piyush Grover, Jessica C. Hassel, Michael Erdmann, Andrea Forschner, Douglas B. Johnson, Renáta Váraljai, Georg Lodde, Jan Malte Placke, Frederik Krefting, Anne Zaremba, Selma Ugurel, Alexander Roesch, Carsten Schulz, Carola Berking, Christoph Pöttgen, Alexander M. Menzies, Georgina V. Long, Reinhard Dummer, Elisabeth Livingstone, Dirk Schadendorf, Lisa Zimmer
Effective treatment options are limited for patients with advanced melanoma who have progressed on immune checkpoint inhibitors (ICI) and targeted therapies (TT). Preclinical models support the combination of ICI with TT; however, clinical trials evaluating the efficacy of triplet combinations in first-line setting showed limited advantage compared to TT only. We conducted a retrospective, multicenter
-
Venetoclax plus cytarabine and azacitidine in relapsed/refractory AML: An open-label, single-arm, phase 2 study Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-01 Liangshun You, Yi Liu, Wenyuan Mai, Wanzhuo Xie, De Zhou, Liping Mao, Lili Chen, Xinping Zhou, Liya Ma, Xiaolong Zheng, Juying Wei, Yinjun Lou, Xingnong Ye, Hongyan Tong, Jie Jin, Haitao Meng
The outcome of relapsed/refractory (R/R) acute myeloid leukemia (AML) remains extremely poor. Venetoclax (VEN)-based regimens have shown promise in treating R/R AML. This phase 2 study aimed to systematically evaluate the efficacy and safety of the VAA regimen (VEN plus Cytarabine and Azacitidine) in R/R AML patients. Thirty R/R AML patients were enrolled. The study adopted a stepwise ramp-up of VEN
-
Survival trends for patients diagnosed with cutaneous malignant melanoma in the Nordic countries 1990-2016: The NORDCAN survival studies Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-01 Frida E. Lundberg, Helgi Birgisson, Gerda Engholm, Elínborg J. Ólafsdóttir, Lina Steinrud Mørch, Tom Børge Johannesen, David Pettersson, Mats Lambe, Karri Seppä, Paul C. Lambert, Anna L.V. Johansson, Lisbet Rosenkrantz Hölmich, Therese M.-L. Andersson
The survival in patients diagnosed with cutaneous malignant melanoma (CMM) has improved in the Nordic countries in the last decades. It is of interest to know if these improvements are observed in all ages and for both women and men. Patients diagnosed with CMM in the Nordic countries in 1990–2016 were identified in the NORDCAN database. Flexible parametric relative survival models were fitted, except
-
Reconciling the discrepancies in randomized data of combining immunotherapy and radiation therapy: Not all radiotherapy is created equal Eur. J. Cancer (IF 8.4) Pub Date : 2024-02-28 Joe Y. Chang, Vivek Verma, Ralph R. Weichselbaum
It remains highly unclear and debatable whether combining radiotherapy (RT) and immune checkpoint blocker (ICB) therapy yields improved outcomes compared to either modality alone. Whereas some randomized data have shown improved outcomes, others have not. As a result of these conflicting data, it is essential to reconcile differences in the data and postulate reasons thereof. This work seeks to address
-
The European Network for Sinonasal Cancer Research (EUSICA) – A pan-European initiative targeting a group of orphan tumours Eur. J. Cancer (IF 8.4) Pub Date : 2024-02-22 Mario Hermsen, Paolo Bossi, David Capper, Jason Fleming, Johannes Haybaeck, Eva Martinez Balibrea, Sandra Nuyts, Alena Skalova, David Thomson, Annalisa Trama, Mario Turri-Zanoni, Benjamin Verillaud, Robbie Woods, Christian von Buchwald, Matt Lechner
-
A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for ≥3rd-line treatment of patients with advanced pancreatic adenocarcinoma Eur. J. Cancer (IF 8.4) Pub Date : 2024-02-22 T. Enzler, A. Nguyen, J. Misleh, V.J. Cline, M. Johns, N. Shumway, S. Paulson, R. Siegel, T. Larson, W. Messersmith, D. Richards, J. Chaves, E. Pierce, M. Zalupski, V. Sahai, D. Orr, S.A. Ruste, A. Haun, T. Kawabe
There is no standard of care for ≥ 3rd-line treatment of metastatic pancreatic adenocarcinoma (PDAC). CBP501 is a novel calmodulin-binding peptide that has been shown to enhance the influx of platinum agents into tumor cells and tumor immunogenicity. This study aimed to (1) confirm efficacy of CBP501/cisplatin/nivolumab for metastatic PDAC observed in a previous phase 1 study, (2) identify combinations
-
Impact of central nervous system metastasis after complete resection of lung adenocarcinomas harboring common EGFR mutation – A real-world database study in Japan: The CReGYT-01 EGFR study Eur. J. Cancer (IF 8.4) Pub Date : 2024-02-22 Shinya Katsumata, Mototsugu Shimokawa, Akira Hamada, Naoki Haratake, Kotaro Nomura, Kosuke Fujino, Mao Yoshikawa, Ken Suzawa, Kazuhiko Shien, Kenichi Suda, Shuta Ohara, Shota Fukuda, Fumihiko Kinoshita, Kazuki Hayasaka, Hirotsugu Notsuda, Shinkichi Takamori, Satoshi Muto, Yusuke Takanashi, Kiyomichi Mizuno, Akikazu Kawase, Takamitsu Hayakawa, Keigo Sekihara, Michihito Toda, Somei Matsuo, Kyoshiro Takegahara
To clarify the impact of central nervous system (CNS) metastasis on performance status (PS) at relapse, on subsequent treatment(s), and on survival of patients with lung adenocarcinoma harboring common epidermal growth factor receptor () mutation. We conducted the multicenter real-world database study for patients with radical resections for lung adenocarcinomas between 2015 and 2018 at 21 centers
-
Thyroid dysfunction after immune checkpoint inhibitors in a single-centre UK pan-cancer cohort: A retrospective study Eur. J. Cancer (IF 8.4) Pub Date : 2024-02-21 Oliver John Kennedy, Nadia Ali, Rebecca Lee, Phillip Monaghan, Safwaan Adam, Tim Cooksley, Paul Lorigan
This study investigated thyroid dysfunction with immune checkpoint inhibitors (ICIs) in terms of proportions affected, risk factors, thyroid sequelae, and overall survival (OS). Among patients with normal baseline free T4 (fT4) and thyroid stimulating hormone (TSH) receiving ICIs at a large cancer centre, proportions of hyperthyroidism/hypothyroidism were determined (any, subclinical [normal fT4, abnormal
-
Corrigendum to “Despite multi-disciplinary team discussions the socioeconomic disparities persist in the oncological treatment of non-metastasized colorectal cancer” [Eur J Cancer 199 (2024) 113572] Eur. J. Cancer (IF 8.4) Pub Date : 2024-02-20 Erik Osterman, Elisavet Syriopoulou, Anna Martling, Therese M.-L. Andersson, Caroline Nordenvall
-
-
Equal censoring but still informative: When the reasons for censoring differ between treatment arms Eur. J. Cancer (IF 8.4) Pub Date : 2024-02-17 Timothée Olivier, Vinay Prasad
In randomized controlled trials, informative censoring has been described as a potential bias, mainly affecting time-to-event composite endpoints, like progression-free survival (PFS). It is usually suspected in the presence of unequal attrition rates between arms. Early censoring occurs for different reasons: patients may withdraw from a trial because of toxicity, or because of disappointment with
-
EORTC QLQ-C30 normative data for the United Kingdom: Results of a cross-sectional survey of the general population Eur. J. Cancer (IF 8.4) Pub Date : 2024-02-17 Teresa Young, Galina Velikova, Gregor Liegl, Matthias Rose, Sandra Nolte, on behalf of the EORTC Quality of Life Group
The cancer-specific health-related quality of life (HRQoL) questionnaire of the European Organisation for Research and Treatment of Cancer (EORTC), the EORTC QLQ-C30, is a frequently applied questionnaire to assess cancer patients’ self-reported health used as part of research and clinical practice. Normative data obtained from the general population can facilitate the interpretation of these data
-
Real-world treatment patterns and outcomes for patients with multiple myeloma in Denmark, Finland and Sweden: An analysis using linked Nordic registries Eur. J. Cancer (IF 8.4) Pub Date : 2024-02-15 Niels Abildgaard, Pekka Anttila, Anders Waage, Katrine Hass Rubin, Sigurd Ørstavik, Nawal Bent-Ennakhil, François Gavini, Yuanjun Ma, Jonatan Freilich, Markus Hansson
The Health outcomes and Understanding of MyelomA multi-National Study (HUMANS) was a large-scale, retrospective study conducted across Denmark, Finland and Sweden using linked data from national registries. We describe the characteristics, treatment patterns and clinical outcomes for patients with newly diagnosed multiple myeloma (NDMM) over 2010–2018. Patients with NDMM who received MM-specific, first-line
-
Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer – Results of a phase 1b clinical trial Eur. J. Cancer (IF 8.4) Pub Date : 2024-02-15 Danmei Zhang, C. Benedikt Westphalen, Michael Quante, Dirk T. Waldschmidt, Swantje Held, Fabian Kütting, Klara Dorman, Kathrin Heinrich, Lena Weiss, Myrto Boukovala, Michael Haas, Stefan Boeck, Volker Heinemann, Victoria Probst
The combination of gemcitabine/nab-paclitaxel is an established standard treatment in the first-line treatment of metastatic ductal adenocarcinoma of the pancreas (mPDAC). Afatinib, an oral second-generation pan ErbB family tyrosine kinase inhibitor, has shown promising pre-clinical signs in the treatment of pancreatic cancer. The aim of this phase 1b trial was to determine the maximum tolerated dose
-
Clinical trial inclusion in patients with relapsed/refractory neuroblastoma following the European Precision Cancer Medicine trial MAPPYACTS Eur. J. Cancer (IF 8.4) Pub Date : 2024-02-15 Jordane Chaix, Gudrun Schleiermacher, Nadège Corradini, Nicolas André, Estelle Thebaud, Marion Gambart, Anne-Sophie Defachelles, Natacha Entz-Werle, Pascal Chastagner, Émilie De Carli, Stéphane Ducassou, Judith Landman-Parker, Tiphaine Adam-de-Beaumais, Alicia Larive, Stefan Michiels, Gilles Vassal, Dominique Valteau-Couanet, Birgit Geoerger, Pablo Berlanga
Despite poor survival for patients with relapsed or refractory neuroblastoma, only 10–16% of patients are reported to be included in early phase trials. This study aimed to explore the impact of molecular profiling within the prospective precision cancer medicine trial MAPPYACTS (NCT02613962) on subsequent early phase trial recruitment and treatment by matched targeted therapies in this population
-
Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in Germany Eur. J. Cancer (IF 8.4) Pub Date : 2024-02-14 Jan A. Stratmann, Friederike C. Althoff, Paula Doebel, Jacqueline Rauh, Arne Trummer, Ali Nuri Hünerlitürkoglu, Nikolaj Frost, Hüsameddin Yildirim, Petros Christopoulos, Oswald Burkhard, Christian Meyer zum Büschenfelde, Aaron Becker von Rose, Jürgen Alt, Sven P. Aries, Maximilian Webendörfer, Stefan Kaldune, Mark Uhlenbruch, Guergana Tritchkova, Cornelius F. Waller, Achim Rittmeyer, Petra Hoffknecht
Sotorasib is a first-in-class p.G12C-inhibitor that has entered clinical trials in pretreated patients with non-small cell lung cancer (NSCLC) in 2018. First response rates were promising in the CodeBreaK trials. It remains unclear whether response to sotorasib and outcomes differ in a real-world setting when including patients underrepresented in clinical trials. Patients with p.G12C-mutated advanced
-
Molecular Tumor Boards: On the evolution of species Eur. J. Cancer (IF 8.4) Pub Date : 2024-02-13 Patrizio Giacomini, Gennaro Ciliberto
-
Real-world data on malignant and borderline phyllodes tumors of the breast: A population-based study of all 921 cases in the Netherlands (1989 −2020) Eur. J. Cancer (IF 8.4) Pub Date : 2024-02-10 Sanne A.L. Bartels, Josefien P. van Olmen, Astrid N. Scholten, Elise M. Bekers, Caroline A. Drukker, Marie-Jeanne T.F.D. Vrancken Peeters, Frederieke H. van Duijnhoven
The aim of our study is to analyze patterns in treatment and outcome in a population-based series of patients with borderline and malignant phyllodes tumors (PT). Data on all patients with a borderline or malignant PT (1989–2020) were extracted from the Netherlands Cancer Registry and the Dutch nationwide pathology databank (Palga) and retrospectively analyzed. We included 921 patients (borderline
-
Carcinomas of the external auditory canal: Management and results: A multicenter REFCOR propensity score matching study Eur. J. Cancer (IF 8.4) Pub Date : 2024-02-10 Esteban Brenet, Sarah Atallah, Joanne Guerlain, Antoine Moya-Plana, Benjamin Verillaud, Romain Kania, David Bakhos, Pierre Philouze, Christian-Adrien Righini, Alexis Bozorg, Jean-Claude Mérol, Marc Labrousse, Sébastien Vergez, Nicolas Fakhry, Patrice Gallet, Dorian Cullié, Olivier Malard, Olivier Mauvais, Léa Fath, Philippe Schultz, Xavier Dufour, Nicolas Saroul, Diane Evrard, Maria Lesnik, Caroline
To analyse prognostic factors and survival outcomes of malignant tumors of the external auditory canal, to investigate the role of regional surgery, and adjuvant radiotherapy in early stages and to investigate the role of surgery in operable T4 stage. A retrospective analysis was conducted on all patients prospectively included in the national database of the French Expertize Network for Rare ENT Cancers
-
Evaluating regulatory consistency for international anti-PD-(L)1 clinical trials Eur. J. Cancer (IF 8.4) Pub Date : 2024-02-10 Albert Q. Wu, David J. Benjamin, Vinay Prasad, Timothée Olivier
-
Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer Eur. J. Cancer (IF 8.4) Pub Date : 2024-02-10 Hiroyuki Arai, Yan Yang, Yasmine Baca, Joshua Millstein, Tadamichi Denda, Fang-Shu Ou, Federico Innocenti, Hiroyuki Takeda, Yohei Kubota, Ayako Doi, Yoshiki Horie, Kumiko Umemoto, Naoki Izawa, Jingyuan Wang, Francesca Battaglin, Priya Jayachandran, Sandra Algaze, Shivani Soni, Wu Zhang, Richard M. Goldberg, Michael J. Hall, Aaron James Scott, Jimmy J. Hwang, Emil Lou, Benjamin A. Weinberg, John Marshall
CDC37 is a key determinant of client kinase recruitment to the HSP90 chaperoning system. We hypothesized that kinase-specific dependency on CDC37 alters the efficacy of targeted therapies for metastatic colorectal cancer (mCRC). Two independent mCRC cohorts were analyzed to compare the survival outcomes between -high and -low patients (stratified by the median cutoff values): the CALGB/SWOG 80405 trial
-
Differentiation of survival outcomes by anatomic involvement and histology with the revised 2023 International Federation of Gynecology and Obstetrics staging system for endometrial cancer Eur. J. Cancer (IF 8.4) Pub Date : 2024-02-10 Nicholas Gravbrot, Christopher R. Weil, Cristina M. DeCesaris, David K. Gaffney, Gita Suneja, Lindsay M. Burt
The International Federation of Gynecology and Obstetrics (FIGO) staging system for endometrial cancer underwent revision in 2023, incorporating histology, lymphovascular space invasion, and molecular classification. Herein, we compare overall survival (OS) outcomes by anatomic and histologic involvement for patients staged by the 2009 system versus 2023 system. The National Cancer Database (NCDB)
-
Evolution of HER2 expression between pre-treatment biopsy and residual disease after neoadjuvant therapy for breast cancer Eur. J. Cancer (IF 8.4) Pub Date : 2024-02-10 Paolo Tarantino, Ogheneochuko Ajari, Noah Graham, Julie Vincuilla, Tonia Parker, Melissa E. Hughes, Nabihah Tayob, Ana C. Garrido-Castro, Stefania Morganti, Tari A. King, Elizabeth A. Mittendorf, Giuseppe Curigliano, Nancy U. Lin, Sara M. Tolaney
We have previously found that HER2 expression is dynamic, and can change from the primary breast tumor to matched recurrences. With this work, we aimed to assess the dynamics of HER2 during neoadjuvant treatment.(NAT). We reviewed HER2 expression in pre- and post-treatment samples from consecutive patients with early-stage breast cancer that received NAT and underwent surgery at Dana-Farber Brigham
-
Isolated melanoma cells in sentinel lymph node in stage IIIA melanoma correlate with a favorable prognosis similar to stage IB Eur. J. Cancer (IF 8.4) Pub Date : 2024-02-10 Teresa Amaral, Lena Nanz, Rudolf Stadler, Carola Berking, Anja Ulmer, Andrea Forschner, Andreas Meiwes, Frederik Wolfsperger, Francisco Meraz-Torres, Eftychia Chatziioannou, Peter Martus, Lukas Flatz, Claus Garbe, Ulrike Leiter
The American Joint Committee on Cancer 8th edition (AJCC v8) defines sentinel lymph nodes (SLN) containing any tumor cells as positive SLN. Consequently, even thin melanomas with isolated tumor cells (ic) in SLN are classified as stage IIIA, making them candidates for adjuvant therapy. We aimed to evaluate survival outcomes of melanoma stage IIIA (ic) and compare them with stage IIIA with lymph node
-
An audit of 1632 routinely collected cervical cancer screening smears from 398 women in Germany: Results from the TeQaZ Study Eur. J. Cancer (IF 8.4) Pub Date : 2024-02-09 Luana F. Tanaka, Olaf Schoffer, Dirk Schriefer, Gunther Schauberger, Hans Ikenberg, Stefanie J. Klug
There is evidence in Germany that half of the cervical cancer (CC) cases had undergone screening frequently in the decade preceding their diagnosis, signaling cytology quality issues. This study investigates routine smear assessment accuracy in Germany. Within a population-based case-control study in 9 German states, we recruited cases (women with a histologically confirmed diagnosis of CC) and population
-
-
Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies Eur. J. Cancer (IF 8.4) Pub Date : 2024-02-06 Alessandro Parisi, Blandine Delaunay, Giada Pinterpe, Antoine Hollebecque, Jean Frederic Blanc, Mohamed Bouattour, Eric Assenat, Meher Ben Abdelghani, Matthieu Sarabi, Monica Niger, Caterina Vivaldi, Mario Mandalà, Andrea Palloni, Maria Bensi, Silvio Ken Garattini, David Tougeron, Pierre Combe, Massimiliano Salati, Margherita Rimini, Chiara Alessandra Cella, Marco Tucci, Anna Diana, Elena Mori, Raffaella
Pemigatinib is approved for patients with pretreated, locally advanced or metastatic CCA harboring FGFR2 rearrangements or fusions. We aim to assess the effectiveness and safety of pemigatinib in real-world setting. A joint analysis of two multicentre observational retrospective cohort studies independently conducted in France and Italy was performed. All consecutive FGFR2-positive patients affected
-
First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17 Eur. J. Cancer (IF 8.4) Pub Date : 2024-02-05 Michael Mark, Patrizia Froesch, Katrin Gysel, Sacha I. Rothschild, Alfredo Addeo, Christoph J. Ackermann, Sabrina Chiquet, Martina Schneider, Karin Ribi, Angela Fischer Maranta, Sara Bastian, Roger von Moos, Markus Joerger, Martin Früh
The safety and efficacy of first-line durvalumab in PS2 patients with advanced NSCLC is unknown. Here, we present the primary analysis of first-line durvalumab in PS2 patients, unsuitable for combination chemotherapy. In this single-arm, multicenter, phase II trial patients with PD-L1 positive (tumor proportional score ≥25%), advanced NSCLC with PS2, received four-weekly durvalumab 1500 mg. The primary
-
Burden of comorbidities: Osteoporotic vertebral fracture during non-small cell lung cancer - the BONE study Eur. J. Cancer (IF 8.4) Pub Date : 2024-02-05 E. Ebstein, P. Brocard, G. Soussi, R. Khoury, M. Forien, A. Khalil, C. Vauchier, P.A. Juge, B. Léger, S. Ottaviani, P. Dieudé, G. Zalcman, V. Gounant
-
Effectiveness and safety of COVID-19 vaccination in people with blood cancer Eur. J. Cancer (IF 8.4) Pub Date : 2024-02-05 Emma Copland, Jennifer Hirst, Emma Mi, Martina Patone, Daniel Chen, Carol Coupland, Julia Hippisley-Cox
People with blood cancer have increased risk of severe COVID-19 outcomes and poor response to vaccination. We assessed the safety and effectiveness of COVID-19 vaccines in this vulnerable group compared to the general population. Individuals aged ≥12 years as of 1st December 2020 in the QResearch primary care database were included. We assessed adjusted COVID-19 vaccine effectiveness (aVE) against
-
Letter re: Impact of EDP-M on survival of patients with metastatic adrenocortical carcinoma: A population-based study Eur. J. Cancer (IF 8.4) Pub Date : 2024-02-05 Marta Laganà, Deborah Cosentini, Guido Alberto Massimo Tiberio, Sandra Sigala, Alfredo Berruti
Abstract not available
-
Real-world health-related quality of life outcomes for patients with resected stage III/IV melanoma treated with adjuvant anti-PD1 therapy Eur. J. Cancer (IF 8.4) Pub Date : 2024-02-04 Mees Egeler, Julia Lai-Kwon, Renaud Tissier, Itske Fraterman, Anke Kuijpers, Winan Van Houdt, Sofie Wilgenhof, Aparna Rao, Shahneen Sandhu, Rebecca Lee, Hanna Eriksson, Marieke van Leeuwen, Kelly de Ligt, Alexander van Akkooi, Lonneke van de Poll-Franse
While adjuvant therapy with anti-programmed cell death protein-1 (anti-PD1) for patients with resected stage III/IV melanoma has been shown to improve recurrence-free survival, the overall survival benefit remains uncertain. This study aims to evaluate the impact of adjuvant anti-PD1 therapy on the health-related quality of life (HRQOL) of patients with resected stage III/IV melanoma Data was used
-
Safety and efficacy of nivolumab in elderly patients with metastatic clear cell renal cell carcinoma: Analysis of the NIVOREN GETUG-AFU 26 study Eur. J. Cancer (IF 8.4) Pub Date : 2024-02-03 Loïc Mourey, Larissa Tames Rainho, Cécile Dalban, Lucía Carril-Ajuria, Sylvie Negrier, Christine Chevreau, Gwenaëlle Gravis, Constance Thibault, Brigitte Laguerre, Philippe Barthelemy, Delphine Borchiellini, Marine Gross-Goupil, Lionnel Geoffrois, Frederic Rolland, Antoine Thiery-Vuillemin, Florence Tantot, Nathalie Chaput, Marie Naigeon, Marcus Teixeira, Bernard Escudier, Ronan Flippot, Laurence Albiges
Immune checkpoint inhibitors are standard of care in metastatic renal cell carcinoma but their activity and safety in elderly patients is insufficiently explored. We evaluated outcomes of elderly patients with mRCC treated with nivolumab in the GETUG-AFU 26 NIVOREN phase 2 trial (NCT03013335) and conducted exploratory circulating biomarker analyses. Patients with mRCC were treated with nivolumab after
-
Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): Final overall survival results from a randomized phase 3 trial Eur. J. Cancer (IF 8.4) Pub Date : 2024-01-28 Véronique Diéras, Hyo S. Han, Hans Wildiers, Michael Friedlander, Jean-Pierre Ayoub, Shannon L. Puhalla, Delphine Loirat, Christine Ratajczak, Hephzibah Adamu, Vincent Girardi, Banu K. Arun
Background In the BROCADE3 study, the addition of veliparib to carboplatin plus paclitaxel resulted in a significant improvement in progression-free survival (PFS) compared with placebo plus carboplatin and paclitaxel, in patients with germline BRCA1 or BRCA2 (BRCA1/2)-mutated, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. We now report final overall survival (OS)
-
TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16) Eur. J. Cancer (IF 8.4) Pub Date : 2024-02-02 Ilaria Colombo, Kira-Lee Koster, Lisa Holer, Simon Haefliger, Manuela Rabaglio, Sara Bastian, Michael Schwitter, Katrin Eckhardt, Stefanie Hayoz, Anna M. Mc Laughlin, Charlotte Kloft, Marian Klose, Stefan Halbherr, Christian Baumgartner, Cristiana Sessa, Anastasios Stathis, Dagmar Hess, Markus Joerger
TLD-1 is a novel liposomal doxorubicin that compared favorably to conventional doxorubicin liposomal formulations in preclinical models. This phase I first-in-human study aimed to define the maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), safety and preliminary activity of TLD-1 in patients with advanced solid tumors. We recruited patients with advanced solid tumors who failed standard